阿替佐利珠单抗治疗晚期肝细胞癌后并发横贯性脊髓炎一例。

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Pub Date : 2023-07-25 DOI:10.4166/kjg.2023.054

Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon

{"title":"阿替佐利珠单抗治疗晚期肝细胞癌后并发横贯性脊髓炎一例。","authors":"Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon","doi":"10.4166/kjg.2023.054","DOIUrl":null,"url":null,"abstract":"The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.","PeriodicalId":22736,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":"82 1","pages":"35-39"},"PeriodicalIF":0.6000,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma.\",\"authors\":\"Kyung Han Kim, Yang-Hyun Baek, Yeo Wool Kang, Byeol-A Yoon, Sang Yi Moon\",\"doi\":\"10.4166/kjg.2023.054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.\",\"PeriodicalId\":22736,\"journal\":{\"name\":\"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi\",\"volume\":\"82 1\",\"pages\":\"35-39\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4166/kjg.2023.054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4166/kjg.2023.054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

IMbrave150研究的结果已导致atezolizumab和贝伐单抗的联合治疗被广泛用作不可切除或转移性肝细胞癌（HCC）的一线治疗。与传统的细胞毒性化疗药物相比，免疫检查点抑制剂表现出一系列副作用，从轻微的副作用（如皮疹）到潜在的严重全身作用（如心肌炎）。我们报告了一例在atezolizumab和贝伐单抗联合治疗HCC期间诊断为横贯性脊髓炎的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Case of Transverse Myelitis Following Treatment with Atezolizumab for Advanced Hepatocellular Carcinoma.

The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi Medicine-Medicine (all)

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

24 weeks